In this episode of the Oncology Brothers podcast, we dived into the exciting world of cancer treatment with a focus on the recent FDA approval of Ziftomenib for relapsed refractory NPM1 mutated acute myeloid leukemia (AML). 

We were joined by Dr. Eunice Wang from Roswell Park Comprehensive Cancer Center as our guest. Dr. Wang shared insights from the KOMET-001 study, detailing the study design, efficacy, and safety profile of Ziftomenib. With a response rate of nearly 30% and significant overall survival benefits for patients, this new treatment option is a promising step forward in managing heavily pretreated AML.

Key topics covered in this episode included:

Whether you're a healthcare professional, a patient, or simply interested in the latest advancements in cancer therapy, this episode is packed with valuable information. 

Follow us on social media:

Don't forget to like, subscribe, and check out our other episodes for more insights into FDA approvals, toxicity management, and practice-changing conference highlights.

#Ziftomenib #MeninInhibitor #AML #NPM1 #Leukemia #FDAapproval #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we dive into the management of ROS1 fusion positive non-small cell lung cancer (NSCLC) and explore the various tyrosine kinase inhibitors (TKIs) available for this rare subset of patients.

Join us along with special guest Dr. Estelamari Rodriguez, a thoracic medical oncologist from Sylvester Comprehensive Cancer Center, as we discussed:

Follow us on social media:

Don't forget to check out our other ToxCheck episodes, conference highlights, and treatment algorithms. Subscribe for more discussions on bridging the gap between academic research and community practice!

#ROS1 #NSCLC #TKIs #Crizotinib #Repotrectinib #Entrectinib #Taletrectinib #TargetedTherapy #OncologyBrothers #LungCancer

In this episode of the Oncology Brothers podcast, we are joined by esteemed hematologists Dr. Onyee Chan from Moffitt Cancer Center and Dr. Fadi Haddad from MD Anderson to discuss the management of side effects associated with tyrosine kinase inhibitors (TKIs) used in the treatment of chronic myeloid leukemia (CML).

Welcome to another episode of the Oncology Brothers podcast! In this episode, we are joined by Dr. Rami Manochakian from the Mayo Clinic to discuss the latest practice-changing studies presented at ESMO 2025, focusing on lung cancer.

Episode Highlights:

Join us as we explore these important studies and their implications for improving patient outcomes in lung cancer care. 

Follow us on social media:

Don't forget to subscribe for more updates on practice-changing research and major conference highlights!

#ESMO2025 #LungCancer #NSCLC #MDT #Zongertinib #Sevabertinib #Osimertinib #OncologyBrothers

In this episode of the Oncology Brothers podcast, we dived into the key takeaways from ESMO 2025, focusing on gastrointestinal (GI) malignancies. Join us as we welcomed Dr. Rachna Shroff, a GI medical oncologist from the University of Arizona, to discuss the latest studies and their implications for clinical practice.

Episode Highlighted:

Tune in for an insightful discussion that highlights the latest advancements in oncology and their potential impact on patient care. 

Follow us on social media:

Don't forget to check out our previous episodes for more insights on conference highlights, recent approvals, and treatment algorithms.

#ESMO2025 #GIOcology #ctDNA #ColorectalCancer #Immunotherapy #OncologyBrothers #PrecisionMedicine

In this episode of the Oncology Brothers podcast, we are joined by Dr. Virginia Kaklamani from UT San Antonio to discuss the practice changing/informing findings from ESMO 2025, particularly in the realm of breast cancer.

We dived deep into the most impactful studies, including:

• MonarchE/NATALEE: Discover additional follow-up results from abemaciclib and ribociclib, where abemaciclib now has overall survival benefit in adjuvant HR+ settings.

Join us as we unpack these complex studies, discuss clinical implications, and share practical insights for community oncologists.

Follow us on social media:

Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

#ESMO2025 #BreastCancer #MonarchE #NATALEE #DESTINYtrials #CDK4/6 #ADCs #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we are joined by Dr. Sharyn Lewin, the Director of Gynecology Oncology at Holy Name Medical Center, to explore the evolving treatment landscape of ovarian cancer.

Join us as we discuss:

Dr. Lewin shared her expertise on the latest clinical data, treatment strategies, and the implications of testing for patients and their families.

Follow us on social media:

Don't forget to like, subscribe, and hit the notification bell to stay updated on our upcoming episodes, including our next discussion on endometrial cancer!

#OvarianCancer #PARPinhibitors #GermlineTesting #GynOnc #OncologyBrothers #MaintenanceTherapy #PersonalizedMedicine

In this episode of the Oncology Brothers podcast, we dive into the groundbreaking data presented at ESMO 2025, focusing on the GU landscape, particularly prostate and bladder cancer. Join us as we welcome Dr. Stephanie Berg, a GU medical oncologist from the Dana-Farber Cancer Institute, to discuss key studies and their implications for patient care.

Episode Highlights:

Stay tuned as we navigate the complexities of treatment options, side effects, and the importance of patient-centered decision-making in oncology. 

Follow us on social media:

Don't forget to subscribe for more insights on treatment algorithms, FDA approvals, and conference highlights!

#ESMO2025 #GUOncology #LutetiumPSMA #Enfortumab #BladderCancer #ProstateCancer #OncologyBrothers

Join us for another insightful episode of The Oncology Brothers as we dive into the Challenging Case Series! In this episode, we were joined by Dr. Eric Singhi, a thoracic medical oncologist from MD Anderson, to discuss the complexities of treating EGFR-positive non-small cell lung cancer (NSCLC).

We explored the latest treatment options, including:

Listen in as we analyze real-life patient cases, focusing on a 58-year-old gentleman with CNS involvement and a 66-year-old woman experiencing disease progression after initial treatment. Dr. Singhi shared valuable insights on the importance of supportive care, the impact of treatment combinations, and the significance of repeat tissue profiling.

Key topics covered:

Whether you're a healthcare professional or simply interested in oncology, this episode is packed with essential information and expert perspectives. 

Follow us on social media:

Don't forget to like, subscribe, and hit the notification bell for more episodes from The Oncology Brothers!

#EGFRNSCLC #Mariposa #Amivantamab #Osimertinib #FLAURA2 #OncologyBrothers #LungCancer

In this episode of Oncology Brothers, we dived deep into the world of CDK4-6 inhibitors, focusing on their side effects and management in breast cancer treatment. Joined by an esteemed guest, Dr. Stephanie Graff, a medical breast oncologist from Brown University Health. We explored the side effects and management strategies for three commonly used CDK4/6 inhibitors: ribociclib, abemaciclib, and palbociclib.

Key topics discussed include:

Whether you're a healthcare professional or someone interested in oncology, this episode provides valuable insights into optimizing patient care while managing the complexities of CDK4-6 inhibitors.

Follow us on social media:

Don't forget to like, subscribe, and check out our other episodes for more discussions on oncology treatments and patient management strategies!

#CDK4/6inhibitors #BreastCancer #Ribociclib #Abemaciclib #Palbociclib #OncologyBrothers #SideEffectManagement #HRpositiveBC